Evaluating second-line treatment options for type 2 diabetes: Focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors;Evaluación de opciones de tratamiento de segunda línea para la diabetes tipo 2: Principalmente los efectos secundarios de los agonistas de GLP-1 y los inhibidores de DPP-4

Annals of Pharmacotherapy

Volumn 47, Issue 4, 2013, Pages 490-505

  Boland, Cassie L ^a   DeGeeter, Michelle ^a   Nuzum, Donald S ^a   Tzefos, Maria ^b  

^a WINGATE UNIVERSITY   (United States)

^b NOVO NORDISK INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ABC TRANSPORTER A1; ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; ADIPONECTIN; C REACTIVE PROTEIN; COLESEVELAM; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INCRETIN; INSULIN; INSULIN DETEMIR; INSULIN GLARGINE; LINAGLIPTIN; LIRAGLUTIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PIOGLITAZONE; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; ROSIGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA; TRIACYLGLYCEROL;

AREA UNDER THE CURVE; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR RISK; CELL PROTECTION; CHOLESTEROL BLOOD LEVEL; DEGRANULATION; DIASTOLIC BLOOD PRESSURE; DISEASE COURSE; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; GLUCOSE TRANSPORT; GLYCEMIC CONTROL; HEART EJECTION FRACTION; HEART FAILURE; HEART INFARCTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INCIDENCE; INSULIN RESISTANCE; KIDNEY FUNCTION; MEDLINE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PANCREAS ISLET BETA CELL; PANCREATITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SIDE EFFECT; STOMACH EMPTYING; SYSTOLIC BLOOD PRESSURE; THYROID CANCER; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 84876209327     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1R444     Document Type: Article

References (142)

1. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364-79.
2. Handelsman Y, Mechanick JI, Blonde L, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for developing a diabetes mellitus comprehensive care plan. Endocr Pract 2011;17:1-53.
3. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009;15:540-59.
4. Neumiller JJ. Clinical pharmacology of incretin therapies for type 2 diabetes mellitus: implications for treatment. Clin Ther 2011;33:528-76.
5. Holst JJ. The physiology of glucagon-like peptide-1. Physiol Rev 2007; 87:1409-39.
6. Drucker KJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368:1696-705.
7. Standards in medical care in diabetes-2012. Diabetes Care 2012;35:S11-53.
8. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193-203.
9. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA 1999;281:2005-12.
10. Eurich DT, Simpson SH, Majumdar SR, Johnson JA. Secondary failure rates associated with metformin and sulfonylurea therapy for type 2 diabetes. Pharmacotherapy 2005;25:810-6.
11. Cook MN, Girman CJ, Stein PP, Alexander CM, Holman RR. Glycemic control continues to deteriorate after sulfonylureas are added to metformin among patients with type 2 diabetes. Diabetes Care 2005;28:995-1000.
12. McIntosh B, Cameron C, Singh SR, et al. Second-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a systematic review and mixed-treatment comparison meta-analysis. Open Med 2011;5:E35-48.
13. Amiel SA, Dixon T, Mannt R, Jameson K. Hypoglycaemia in type 2 diabetes. Diabet Med 2008;25:245-54.
14. Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009;373:473-81.
15. Smith U. Pioglitazone: mechanism of action. Int J Clin Pract Suppl 2001;121:13-8.
16. Product information. Actos (pioglitazone). Deerfield, IL: Takeda Pharmaceuticals America, Inc., August 2012.
17. Charbonnel BH, Matthews DR, Schernthaner G, Hanefeld M, Brunetti P. A long-term comparison of pioglitazone and gliclazide in patients with type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial. Diabet Med 2005;22:399-405.
18. Aronoff S, Rosenblatt S, Braithwaite S, et al. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. Diabetes Care 2000;23:1605-11.
19. Rosenstock J, Dailey G, Massi-Benedetti M, Fritsche A, Zhengning L, Salzman A. Reduced hypoglycemia risk with insulin glargine. Diabetes Care 2005;28:950-5.
20. Blonde L, Merilainen M, Karwe V, Raskin P. Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets-the TITRATE study. Diabetes Obes Metab 2009;11:623-31.
21. Rosenstock J, Davies M, Home PD, Larsen J, Koenen C, Schernthaner G. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia 2008;51:408-16.
22. Hollander P, Cooper J, Bregnhøj J, Pedersen CB. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes. Clin Ther 2008;30:1976-87.
23. Moretto TJ, Milton DR, Ridge TD, et al. Efficacy and tolerability of exen atide monotherapy over 24 weeks in antidiabetic drug-naïve patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2008;30:1448-60.
24. Russell-Jones D, Cuddihy RM, Hanefeld M, et al. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naïve patients with type 2 diabetes (DURATION-4). Diabetes Care 2012;35:252-8.
25. Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006;29:2632-7.
26. Raz I, Hanefeld M, Xu L, Caria C, Williams-Herman D, Khatami H. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 2006;49:2564-71.
27. Rosenstock J, Sankoh S, List JF. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naïve patients with type 2 diabetes. Diabetes Obes Metab 2008;10:376-86.
28. Del Prato S, Barnett AH, Huisman H, Neubacher D, Woerle HJ, Dugi KA. Effect of linagliptin monotherapy on glycaemic control and markers of beta-cell function in patients with inadequately controlled type-2 diabetes: a randomized controlled trial. Diabetes Obes Metab 2011;13:258-67.
29. Klein S, Sheard NF, Pi-Sunyer X, et al.; American Diabetes Association; North American Association for the Study of Obesity; American Society for Clinical Nutrition. Weight management through lifestyle modification for the prevention and management of type 2 diabetes: rationale and strategies: a statement of the American Diabetes Association, the North American Association for the Study of Obesity, and the American Society for Clinical Nutrition. Diabetes Care 2004;27:2067-73.
30. Pi-Sunyer X, Blackburn G, Brancati FL, et al. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: oneyear results of the look AHEAD trial. Diabetes Care 2007;30:1374-83.
31. DeFronzo RA, Okerson T, Viswanathan P, Guan X, Holcombe JH, Mac-Conell L. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. Curr Med Res Opin 2008;24:2943-52.
32. Holst JJ, Deacon CF. Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors. Diabetologia 2005;48:612-5.
33. Herman GA, Bergman A, Stevens C, et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab 2006;91:4612-9.
34. Drucker DJ, Buse JB, Taylor K, et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 2008;372:1240-50.
35. Buse JB, Drucker DJ, Taylor KL, et al. DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. Diabetes Care 2010;33:1255-61.
36. Blevins T, Pullman J, Malloy J, et al. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab 2011;96:1301-10.
37. Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exen-atide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009;374:39-47.
38. Blonde L, Klein EJ, Han J, et al. Interim analysis of the effects of exen-atide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab 2006;8:436-47.
39. Wysham C, Bergenstal R, Malloy J, et al. DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide. Diabet Med 2011;28:705-14.
40. Klonoff DC, Buse JB, Nielsen LL, et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 2008;24:275-86.
41. Ratner RE, Maggs D, Nielsen LL, et al. Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus. Diabetes Obes Metab 2006;8:419-28.
42. Buse JB, Sesti G, Schmidt WE, et al. Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents. Diabetes Care 2010;33:1300-3.
43. Buse JB, Ginsberg HN, Bakris GL, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus. Diabetes Care 2007;30:162-72.
44. Stettler C, Allemann S, Jüni P, et al. Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: meta-analysis of randomized trials. Am Heart J 2006;152:27-38.
45. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil AW. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-89.
46. Gerstein HC, Miller ME, Genuth S, et al. Long-term effects of intensive glucose-lowering on cardiovascular outcomes. N Engl J Med 2011; 364:818-28.
47. Tzoulaki I, Molokhia M, Curcin V, et al. Risk of cardiovascular disease and all-cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ 2009;339:b4731.
48. Evans JM, Ogston SA, Emslie-Smith A, Morris AD. Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia 2006;49:930-6.
49. Abdelmoneim AS, Hasenbank SE, Seubert JM, Brocks DR, Light PE, Simpson SH. Variations in tissue cell activity amongst insulin secretagogues: a systematic review. Diabetes Obes Metab 2012;14:130-8.
50. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356:2457-71.
51. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366:1279-89.
52. Davidson MH. Cardiovascular effects of glucagon-like peptide-1 agonists. Am J Cardiol 2011;108:33B-41B.
53. Nikolaidis LA, Mankad S, Sokos GG, et al. Effect of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 2004;109:962-5.
54. Sokos GG, Nikolaidis LA, Mankad S, Elahi D, Shannon RP. Glucagonlike peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Cardiac Fail 2006;12:694-9.
55. Russell-Jones D, Vaag A, Schmitz O, et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia 2009;52:2046-55.
56. Zinman B, Gerich J, Buse J, et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 MET+TZD). Diabetes Care 2009;32:1224-30.
57. Marre M, Shaw J, Brändle M, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med 2009;26:268-78.
58. Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (Liraglutide Effect and Action in Diabetes)-2 study. Diabetes Care 2009;32:84-90.
59. Gutzwiller JP, Tschopp S, Bock A, et al. Glucagon-like peptide 1 induces natriuresis in healthy participants and in insulin-resistant obese men. J Clin Endocrinol Metab 2004;89:3055-61.
60. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual BP to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903-13.
61. Bergenstal RM, Wysham C, MacConell L, et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet 2010;376:431-9.
62. Vilsbøll T, Zdravkovic M, Le-Thi T, et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care 2007;30:1608-10.
63. Charbonnel B, Karasik A, Liu J, Wu M, Meninger G. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006;29:2638-43.
64. Rigby SP, Handelsman Y, Lai Y, Abby SL, Tao B, Jones MR. Effects of colesevelam, rosiglitazone, or sitagliptin on glycemic control and lipid profile in patients with type 2 diabetes mellitus inadequately controlled by metformin monotherapy. Endocr Pract 2010;16:53-63.
65. Scott R, Loeys T, Davies MJ, et al. Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. Diabetes Obes Metab 2008;10:959-69.
66. Wainstein J, Katz L, Engel SS, et al. Initial therapy with the fixed-dose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetes. Diabetes Obes Metab 2012;14:409-18.
67. Williams-Herman D, Johnson J, Teng R, et al. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as mono-therapy over 2 years in patients with type 2 diabetes. Diabetes Obes Metab 2010;12:442-51.
68. Nauck MA, Meininger G, Sheng D, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2007;9:194-205.
69. Jadzinsky M, Pfützner A, Paz-Pacheco E, et al. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes Obes Metab 2009;11:611-22.
70. Rosenstock J, Aguilar-Salinas C, Klein E, et al. Effects of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes. Curr Med Res Opin 2009;25:2401-11.
71. Brixner DI, McAdam-Marx C, Ye X, et al. Six-month outcomes on A1C and cardiovascular risk factors in patients with type 2 diabetes treated with exenatide in an ambulatory care setting. Diabetes Obes Metab 2009; 11:1122-30.
72. Violante R, Oliveira HA, Yoon KH, et al. A randomized non-inferiority study comparing the addition of exenatide twice daily to sitagliptin or switching from sitagliptin to exenatide twice daily in patients with type 2 diabetes experiencing inadequate glycaemic control on metformin and sitagliptin. Diabet Med 2012;29:e417-24. doi: 10.1111/j.1464-5491.2012.03624.x
73. Monami M, Cremasco F, Lamanna C, et al. Glucagon-like peptide-1 receptor agonists and cardiovascular events: a meta-analysis of randomized clinical trials. Exp Diabetes Res 2011;2011:215764.
74. Williams-Herman D, Engel SS, Round E, et al. Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes. BMC Endocrine Disorders 2010;10:7.
75. Frederich R, Alexander JH, Fiedorek FT, et al. A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes. Postgrad Med 2010;122:16-27.
76. Johansen OE, Neubacher D, von Eynatten M, Patel S, Woerle H. Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme. Cardiovasc Diabetol 2012;11:3.
77. Fonseca VA. Ongoing clinical trials evaluating the cardiovascular safety and efficacy of therapeutic approaches to diabetes mellitus. Am J Cardiol 2011; 108:52B-8B.
78. Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 1999;104:787-94.
79. Johnson JD, Luciani DS. Mechanisms of pancreatic beta-cell apoptosis in diabetes and its therapies. Adv Exp Med Biol 2010;654:447-62.
80. Turner RC, Cull CA, Stratton IM, et al. UK prospective diabetes study 16-overview of 6 years therapy of type II diabetes-a progressive disease. Diabetes 1995;44:1249-58.
81. Matveyenko AV, Butler PC. Relationship between beta-cell mass and diabetes onset. Diabetes Obes Metab 2008;10:23-31.
82. Shah P, Vella A, Basu A, Basu R, Schwenk WF, Rizza RA. Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 2000;85:4053-9.
83. 2+concentration. J Biol Chem 1998;273:33501-7.
84. Maedler K, Carr RD, Bosco D, Zuellig RA, Berney T, Donath MY. Sulfonylurea induced beta-cell apoptosis in cultured human islets. J Clin Endocrinol Metab 2005;90:501-6.
85. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-43.
86. Hull RL, Shen ZP, Watts MR, et al. Long-term treatment with rosiglitazone and metformin reduces the extent of, but does not prevent, islet amyloid deposition in mice expressing the gene for human islet amyloid polypeptide. Diabetes 2005;54:2235-44.
87. Lin CY, Gurlo T, Haataja L, Hsueh WA, Butler PC. Activation of peroxisome proliferator-activated receptor-gamma by rosiglitazone protects human islet cells against human islet amyloid polypeptide toxicity by a phosphatidylinositol 3p-kinase-dependent pathway. J Clin Endocrinol Metab 2005;90:6678-86.
88. Mu J, Woods J, Zhou YP, et al. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes. Diabetes 2006;55:1695-704.
89. Reimer MK, Holst JJ, Ahren B. Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice. Eur J Endocrinol 2002;146:717-27.
90. Rolin B, Larsen MO, Gotfredsen CF, et al. The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice. Am J Physiol Endocrinol Metab 2002;283:E745-52.
91. Sturis J, Gotfredsen CF, Rømer J, et al. GLP-1 derivative liraglutide in rats with beta-cell deficiencies: influence of metabolic state on beta-cell mass dynamics. Br J Pharmacol 2003;140:123-32.
92. Chen J, Couto FM, Minn AH, Shalev A. Exenatide inhibits beta-cell apoptosis by decreasing thioredoxin-interacting protein. Biochem Biophys Res Commun 2006;346:1067-74.
93. Hanefeld M, Herman GA, Wu M, Mickel C, Sanchez M, Stein PP. Oncedaily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes. Curr Med Res Opin 2007;23:1329-39.
94. Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2006;28:1556-68.
95. Nonaka K, Kakikawa T, Sato A, et al. Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract 2008;79:291-8.
96. Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P. Efficacy and safety of dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab 2007;9:733-45.
97. Hollander P, Li J, Allen E, et al. Saxagliptin added to thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone. J Clin Endocrinol Metab 2009;94:4810-9.
98. DeFronzo RA, Hissa MN, Garber AJ, et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes on metformin alone. Diabetes Care 2009;32:1649-55.
99. Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 2007;30:1979-87.
100. Retnakaran R, Qi Y, Opsteen C, Vivero E, Zinman B. Initial short-term intensive insulin therapy as a strategy for evaluating the preservation of beta-cell function with oral antidiabetic medications: a pilot study with sitagliptin. Diabetes Obes Metab 2010;12:909-15.
101. Seck T, Nauck M, Sheng D, et al. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study. Int J Clin Pract 2010;64:562-76.
102. Yoon KH, Shockey GR, Teng R, et al. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of beta-cell function in patients with type 2 diabetes. Int J Clin Pract 2011;65:154-64.
103. Chang AM, Jakobsen G, Sturis J, et al. The GLP-1 derivative NN2211 restores beta-cell sensitivity to glucose in type 2 diabetic patients after a single dose. Diabetes 2003;52:1786-91.
104. Degn KB, Juhl CB, Sturis J, et al. One week's treatment with the longacting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha-and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes 2004;53:1187-94.
105. Madsbad S, Schmitz O, Ranstam J, et al. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial. Diabetes Care 2004;27:1335-42.
106. Mari A, Degn K, Brock B, Rungby J, Ferrannini E, Schmitz O. Effects of the long-acting human glucagon-like peptide-1 analog liraglutide on betacell function in normal living conditions. Diabetes Care 2007;30:2032-3.
107. Egan JM, Clocquet AR, Elahi D. The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes. J Clin Endocrinol Metab 2002;87:1282-90.
108. Buse JB, Henry RR, Han J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004;27:2628-35.
109. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005;28:1092-100.
110. Product information. Byetta (exenatide). San Diego, CA: Amylin Pharmaceuticals, Inc., December 2011.
111. Product information. Bydureon (exenatide extended-release). San Diego, CA: Amylin Pharmaceuticals, Inc., January 2012.
112. Product information. Januvia (sitagliptin). Whitehouse Station, NJ: Merck & Co., Inc., April 2012.
113. Product information. Onglyza (saxagliptin). Princeton, NJ: Bristol-Myers Squibb Company, December 2011.
114. Product information. Victoza (liraglutide). Princeton, NJ: Novo Nordisk, April 2012.
115. Product information. Tradjenta (linagliptin). Ridgefield, CT: Boehringer-Ingelheim Pharmaceuticals, Inc., September 2012.
116. Crespel A, De Boisvilliers F, Gros L, Kervran A. Effects of glucagon and glucagon-like peptide-1-(7-36) amide on C cells from rat thyroid and medullary thyroid carcinoma CA-77 cell line. Endocrinology 1996; 137:3674-80.
117. Lamari Y, Boissard C, Moukhtar MS, Jullienne A, Rosselin G, Garel JM. Expression of glucagon-like peptide 1 receptor in a murine C cell line: regulation of calcitonin gene by glucagon-like peptide 1. FEBS Lett 1996;393:248-52.
118. Madsen LW, Knauf JA, Gotfredsen C, et al. GLP-1 receptor agonists and the thyroid: C-cell effects in mice are mediated via the GLP-1 receptor and not associated with RET activation. Endocrinology 2012;153: 1538-47.
119. Knudsen LB, Madsen LW, Andersen S, et al. Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology 2010;151:1473-86.
120. Gier B, Butler PC, Lai CK, Kirakossian D, DeNicola MM, Yeh MW. Glucagon like peptide-1 receptor expression in the human thyroid gland. J Clin Endocrinol Metab 2012;97:121-31.
121. Food and Drug Administration. Victoza. Approval. 2010. http://www. access data.fda.gov/drugsatfda_docs/label/2012/022200Orig1s000lbledt. pdf. (accessed 2013 Mar 22).
122. Food and Drug Administration. Bydureon. Approval. 2012. http://www. accessdata.fda.gov/drugsatfda_docs/nda/2012/022200Orig1s000SumR. pdf (accessed 2013 Mar 22).
123. Noel RA, Braun DK, Patterson RE, Bloomgren GL. Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study. Diabetes Care 2004;27:2628-35. www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationfor-PatientsandProviders/ucm124712. (accessed 2013 Mar 22).
124. Food and Drug Administration. Information for healthcare professionals: exenatide (marketed as Byetta). October 2007 update. http://www.fda. gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatients andProviders/ucm124712.htm (accessed 2012 Jun 18). www.fda.gov/ Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsand Providers/ucm124713. (accessed 2013 Mar 22).
125. Food and Drug Administration. Information for healthcare professionals: exenatide (marketed as Byetta). August 2008 update. http://www.fda.gov/ Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsand Providers/ucml124713.htm (accessed 2012 Jun 18).
126. Food and Drug Administration. Byetta (exenatide). Injections detailed view: safety labeling changes approved by FDA Center for Drug Evaluation and Research (CDER). November 2009, November 2010, and October 2011. http://www.Fda.gov/Safety/MedWatch/SafetyInformation/ucm 194556.htm (accessed 2012 Jun 18).
127. Food and Drug Administration. Sitagliptin (marketed as Januvia and Janumet)-acute pancreatitis. http://www.fda.gov/Safety/MedWatch/ SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm183800. htm (accessed 2012 Jun 18).
128. Garg R, Chen W, Pendergrass M. Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis. Diabetes Care 2010;33:2349-54.
129. Wenten M, Gaebler JA, Hussein M, et al. Relative risk of acute pancreatitis in initiators of exenatide twice daily compared with other anti-diabetic medication: a follow-up study. Diabet Med 2012:29:1412-8. doi: 10.1111/j.1464-5491.2012.03652.x
130. MacConell L, Brown C, Gurney K, Han J. Safety and tolerability of exenatide twice daily in patients with type 2 diabetes: integrated analysis of 5594 patients from 19 placebo-controlled and comparator-controlled clinical trials. Diabetes Metab Syndr Obes 2012;5:29-41.
131. Food and Drug Administration. Victoza (liraglutide [rDNA origin]) injection: REMS-risk of thyroid C-cell tumors, acute pancreatitis (posted 06/ 13/2011). http://www.fda.gov/Safety/MedWatch/SafetyInformation/Safety AlertsforHumanMedicalProducts/ucm258826.htm (accessed 2012 Jun 18).
132. Singh S, Chang HY, Richards TM, Weiner JP, Clark JM, Segal JB. Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA Intern Med 2013 Feb 25:E1-6 [Epub ahead of print].
133. FDA Drug Safety Communication: FDA investigating reports of possible increased risk of pancreatitis and pre-cancerous findings of the pancreas from incretin mimetic drugs for type 2 diabetes. www.fda.gov/ Drugs/DrugSafety/ucm343187.htm (accessed 2013 Mar 27).
134. Pioglitazone. Red book online. Greenwood Village, CO: Thomson Reuters (Healthcare) Inc. www.micromedexsolutions.com/micromedex2/librarian/ ND_T/evidence xpert/ND_PR/evidencexpert/CS/86BC76/ND_App Product/evidencexpert/DUPLICATIONSHIELDSYNC/877EB7/ND _PG/evidence xpert/ND_B/evidencexpert/ND_P/evidencexpert/PFAction Id/redbook.ShowProductSearchResults?SearchTerm=PIOGLITAZONE &search Type=redbookProductName&searchTermId=40205&search Content=REDBOOK&searchFilterAD=filterADActive&searchFilter Repackager=filterExcludeRepackager&searchPattern=%5Epioglitazone. (accessed 2012 Nov 5).
135. Lantus. Red book online. Greenwood Village, CO: Thomson Reuters (Healthcare) Inc. www.micromedexsolutions.com/micromedex2/librarian/ ND_T/evidencexpert/ND_PR/evidencexpert/CS/86BC76/N_AppProduct/ evidencexpert/DUPLICATIONSHIELDSYNC/877EB7/ND_PG/ evidencexpert/ND_B/evidencexpert/ND_P/evidencexpert/PFAction Id/redbook.ShowProductSearchResults?SearchTerm=LANTUS%20 SOLOSTAR&searchType=redbookProductName&searchTerm Id=19914&searchContent=REDBOOK&searchFilterAD=filterADActive &searchFilterRepackager=filterExcludeRepackager&searchPattern= %5ELantus. (accessed 2012 Nov 5).
136. Levemir. In: Red book online. Greenwood Village, CO: Thomson Reuters (Healthcare) Inc. www.micromedex solutions.com/micromedex2/librarian/ ND_T/evidencexpert/ND_PR/evidencexpert/CS/86BC76/ND_App Product/evidencexpert/DUPLICATION SHIELDSYNC/877EB7/ND_ PG/evidencexpert/ND_B/ evidencexpert/ND_P/evidencexpert/PFAction Id/redbook.ShowProductSearchResults?SearchTerm=LEVEMIR&search Type=redbookProduct Name&searchTermId=18914&searchContent= REDBOOK&searchFilter AD=filterADActive&searchFilterRepackager =filterExcludeRepackager &searchPattern=%5Elevemir. (accessed 2012 Nov 5).
137. Byetta. In: Red book online. Greenwood Village, CO: Thomson Reuters (Healthcare) Inc. www.micromedexsolutions.com/micromedex2/librarian/ ND_T/evidencexpert/ND_PR/evidencexpert/CS/86BC76/ND_App Product/evidencexpert/DUPLICATIONSHIELDSYNC/877EB7/ND_PG/ evidencexpert/ND_B/evidencexpert/ND_P/evidencexpert/PFActionId/ redbook.ShowProductSearchResults?SearchTerm=BYETTA&search Type=redbookProductName&searchTermId=17855&searchContent= REDBOOK&searchFilterAD=filterADActive&searchFilterRepackager =filterExcludeRepackager&searchPattern=%5Ebyetta. (accessed 2012 Nov 5).
138. Bydureon. In: Red book online. Greenwood Village, CO: Thomson Reuters (Healthcare) Inc. www.micromedexsolutions.com/micromedex2/ librarian/ND_T/evidencexpert/ND_PR/evidencexpert/CS/86BC76/ND_ AppProduct/evidencexpert/DUPLICATIONSHIELDSYNC/877EB7/ND_ PG/evidencexpert/ND_B/evidencexpert/ND_P/evidencexpert/PFActionId/ redbook.ShowProductSearchResults?SearchTerm=BYDUREON&search Type=redbookProductName&searchTermId=39363&searchContent= REDBOOK&searchFilterAD=filterADActive&searchFilterRepackager =filterExcludeRepackager&searchPattern=%5Ebydureon. (accessed 2012 Nov 5).
139. Victoza. In: Red book online. Greenwood Village, CO: Thomson Reuters (Healthcare) Inc. www.micromedexsolutions.com/micromedex2/librarian/ ND_T/evidenc expert/ND_PR/evidencexpert/CS/86BC76/ND_App Product/evidencexpert/DUPLICATIONSHIELDSYNC/877EB7/ND_PG/ evidencexpert/ND_B/evidencexpert/ND_P/evidencexpert/PFActionId/ redbook.ShowProductSearchResults?SearchTerm=VICTOZA&search Type=redbookProductName&searchTermId=22668&searchContent= REDBOOK&searchFilterAD=filterADActive&searchFilterRepackager =filterExcludeRepackager&searchPattern=%5Evictoza. (accessed 2012 Nov 5).
140. Januvia. In: Red book online. Greenwood Village, CO: Thomson Reuters (Healthcare) Inc. www.micromedexsolutions.com/micromedex2/ librarian/ND_T/evidencexpert/ND_PR/evidencexpert/CS/86BC76/ND_ AppProduct/evidencexpert/DUPLICATIONSHIELDSYNC/877EB7/ ND_PG/evidencexpert/ND_B/evidencexpert/ND_P/evidencexpert/ PFActionId/redbook.ShowProductSearchResults?SearchTerm=JANUVIA &searchType=redbookProductName&searchTermId=19065&search Content=REDBOOK&searchFilterAD=filterADActive&searchFilter Repackager=filterExcludeRepackager&searchPattern=%5Ejanuvia. (accessed 2012 Nov 5).
141. Onglyza. In: Red book online. Greenwood Village, CO: Thomson Reuters (Healthcare) Inc. www.micromedexsolutions.com/micromedex2/ librarian/ND_T/evidencexpert/ND_PR/evidencexpert/CS/86BC76/ND_ AppProduct/evidencexpert/DUPLICATIONSHIELDSYNC/877EB7/ ND_PG/evidencexpert/ND_B/evidencexpert/ND_P/evidencexpert/PF ActionId/redbook.ShowProductSearchResults?SearchTerm=ONGLYZA &searchType=redbookProductName&searchTermId=36695&search Content=REDBOOK&searchFilterAD=filterADActive&searchFilter Repackager=filterExcludeRepackager&searchPattern=%5Eonglyza. (accessed 2012 Nov 5).
142. Tradjenta. In: Red book online. Greenwood Village, CO: Thomson Reuters (Healthcare) Inc. www.micromedexsolutions.com/micromedex2/ librarian/ND_T/evidencexpert/ND_PR/evidencexpert/CS/86BC76/ND_ AppProduct/evidencexpert/DUPLICATIONSHIELDSYNC/877EB7/ ND_PG/evidencexpert/ND_B/evidencexpert/ND_P/evidencexpert/ PFActionId/redbook.ShowProductSearchResults?SearchTerm= TRADJENTA&searchType=redbookProductName&searchTermId= 38414&searchContent=REDBOOK&searchFilterAD=filterADActive &searchFilterRepackager=filterExcludeRepackager&searchPattern =%5Etradjenta. (accessed 2012 Nov 5).